Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

NCT01493726 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT01493726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01493726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
Lead sponsor
Alkermes, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2011
Completion date
June 30, 2013
Enrollment
88 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia